In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results, targeting Plasmepsin II, a Plasmodium falciparum aspartic protease active in hemoglobin degradation, a parasite specific catabolic pathway. The results show that the new structural class is not only inhibiting PMII in vitro but is also active in a P. falciparum infected human red blood cell assay.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2006.09.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular insights into the aspartate protease Plasmepsin II activity inhibition by fluoroquinolones: A pathway to antimalarial drug development.
Int J Biol Macromol
January 2025
UM-DAE Centre for Excellence in Basic Sciences, University of Mumbai, Vidyanagri Campus, Kalina, Mumbai 400098, India. Electronic address:
Article Synopsis
- Plasmepsin II (PlmII) is an important enzyme in Plasmodium falciparum that helps in breaking down hemoglobin, making it a key target for new antimalarial drugs.
- Research successfully produced and activated Pro-plasmepsin II, confirming its functionality through various enzyme studies, and identified that norfloxacin and ciprofloxacin can effectively inhibit this enzyme, unlike sparfloxacin.
- The study suggests repurposing these fluoroquinolone antibiotics for malaria treatment, highlighting their mechanism of action at the enzyme’s active site, which could lead to new therapeutic options against malaria.
Advances in protease inhibition-based chemotherapy: A decade of insights from Malaria research.
Adv Parasitol
October 2024
Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic; Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic.
Article Synopsis
- Recent research on the parasite Plasmodium falciparum has advanced our understanding of protease isoenzymes, revealing their unique roles and biochemical features.
- *The findings have led to new chemotherapy options that utilize low molecular weight inhibitors to target specific molecular sites within the parasite.
- *Additionally, advancements in proteasome inhibition and research on vital metalloproteases are paving the way for the potential treatment and study of other lesser-known parasitic diseases.*
Assessing the interplay between off-target promiscuity, cytotoxicity, and tolerability in rodents to improve the safety profile of novel anti-malarial plasmepsin X inhibitors.
Toxicol Sci
October 2024
UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium.
Article Synopsis
- High off-target promiscuity and potent cytotoxicity in drug development can lead to a high failure rate, making safety assessment critical for compounds like novel plasmepsin X (PMX) inhibitors for malaria treatment.
- A total of 249 PMX compounds were tested through various assays, revealing a correlation between high cytotoxicity in liver cells and poor tolerability in animal studies, often associated with specific receptor activities.
- A structured approach using in vitro assays is necessary to identify harmful targets early and improve the chances of selecting safer compounds for further testing.
Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials.
Toxicol Sci
October 2024
UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium.
Quinoline-related antimalarial drugs have been associated with cardiotoxicity risk, in particular QT prolongation and QRS complex widening. In collaboration with Medicines for Malaria Venture, we discovered novel plasmepsin X (PMX) inhibitors for malaria treatment. The first lead compounds tested in anesthetized guinea pigs (GPs) induced profound QRS widening, although exhibiting weak inhibition of NaV1.
View Article and Find Full Text PDFThe malaria parasite egress protease SUB1 is activated through precise, plasmepsin X-mediated cleavage of the SUB1 prodomain.
Biochim Biophys Acta Gen Subj
September 2024
Malaria Biochemistry Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK. Electronic address:
Background: The malaria parasite Plasmodium falciparum replicates within red blood cells, then ruptures the cell in a process called egress in order to continue its life cycle. Egress is regulated by a proteolytic cascade involving an essential parasite subtilisin-like serine protease called SUB1. Maturation of SUB1 initiates in the parasite endoplasmic reticulum with autocatalytic cleavage of an N-terminal prodomain (p31), which initially remains non-covalently bound to the catalytic domain, p54.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!